This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (31)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Psychiatry  • Alert me on articles by topic  Social Bookmarking   What's this?

Ross J. Baldessarini, MD; Leonardo Tondo, MD

JAMA. 2003;290:1517-1519.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Bipolar disorder, one of the most common severe mental illnesses, includes type 1 (with mania and usually recurrent depression) and type 2 (recurrent major depression with hypomania).^1-2 Lifetime prevalence for type 1 bipolar disorder is approximately 1%, but inclusion of more broadly defined conditions increases this rate to 2% to 5%.³ Bipolar disorder can begin in childhood or adolescence,⁴ continues throughout life, and is extraordinarily costly—financially as well as clinically and socially.⁵ The course of bipolar disorder is episodic but highly variable, with potential for high levels of severity and recurrence intensity, disproportionately high depressive morbidity, and comorbidity with substance abuse and anxiety disorders.³ Bipolar depression can be present during 20% to 30% of patients' time, even during prophylactic treatment,^6-8 and is closely associated with disability and mortality.^{3, 9-10} Bipolar disorder proves fatal in a high proportion of patients from complications of risk-taking behavior, . . . [Full Text of this Article]

Author Affiliations: Department of Psychiatry and Neuroscience Program, Harvard Medical School, Boston, Mass (Drs Baldessarini and Tondo); Bipolar and Psychotic Disorders Program and International Consortium for Bipolar Disorder Research, McLean Division of Massachusetts General Hospital, Belmont (Drs Baldessarini and Tondo); Centro Bini–Stanley Medical Research Institute and Department of Psychology, University of Cagliari, Cagliari, Italy (Dr Tondo).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Suicide Risk in Bipolar Disorder During Treatment With Lithium and Divalproex
Frederick K. Goodwin, Bruce Fireman, Gregory E. Simon, Enid M. Hunkeler, Janelle Lee, and Dennis Revicki
JAMA. 2003;290(11):1467-1473.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Identifying Functional Neuroimaging Biomarkers of Bipolar Disorder: Toward DSM-V
Phillips and Vieta
Schizophr Bull 2007;33:893-904.
ABSTRACT | FULL TEXT  

The Relationship Between Antidepressant Prescription Rates and Rate of Early Adolescent Suicide
Gibbons et al.
Am. J. Psychiatry 2006;163:1898-1904.
ABSTRACT | FULL TEXT  

Bipolar Disorder in School-Age Children
Olson and Pacheco
The Journal of School Nursing 2005;21:152-157.
ABSTRACT | FULL TEXT  

The Increasing Medical Burden in Bipolar Disorder
Kupfer
JAMA 2005;293:2528-2530.
FULL TEXT  

The Relationship Between Antidepressant Medication Use and Rate of Suicide
Gibbons et al.
Arch Gen Psychiatry 2005;62:165-172.
ABSTRACT | FULL TEXT  

Suicide Risk Is Lower with Lithium than with Divalproex in Bipolar Patients
JWatch Psychiatry 2003;2003:3-3.
FULL TEXT